Advent Pharma Ltd. announcements
129 Dhaka Stock Exchange announcements for Advent Pharma Ltd. (ADVENT) since 2018: results, dividends, board meetings, AGMs, record dates and other price-sensitive information. Showing 2024 (21).
- Resumption after Record date
Trading of the shares of the company will resume on 21.11.2024.
- Suspension for record date
Trading of the shares of the company will remain suspended on record date i.e., 20.11.2024.
- Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 18.11.2024 to 19.11.2024. Trading of the shares of the company will remain suspended on record date i.e., 20.11.2024.
- Q1 Financials
(Q1 Un-audited): EPS was Tk. 0.16 for July-September 2024 as against Tk. 0.35 for July-September 2023; NOCFPS was Tk. 0.19 for July-September 2024 as against Tk. 0.45 for July-September 2023. NAV per share was Tk. 15.94 as on September 30, 2024 and Tk. 15.78 as on June 30, 2024.
- Emphasis of Matters
The auditor of the company has given the "Emphasis of Matters" paragraphs in the Auditor's Report of the company for the year ended June 30, 2024. To view the details, please visit: https://www.dsebd.org/Auditors_opinion/2024/November/ADVENT_2024.pdf
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 13, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
- The Board of Directors has recommended 1.00\% Cash dividend only for General Shareholders excluding the Sponsors & Direc
The Board of Directors has recommended 1.00\% Cash dividend only for General Shareholders excluding the Sponsors & Directors for the year ended June 30, 2024. The quantities of securities held by the said sponsors and/or directors who will not be entitled to recommended dividend: 27,957,751 shares. The amount payable to the general shareholders is Tk. 6,517,498.10. Date of AGM: 29.12.2024, Time: 12:00 Noon, Venue: Hybrid System. Record Date: 20.11.2024. (cont.)
- Dividend Declaration
(Cont. news of ADVENT): The Company has also reported EPS of Tk. 0.90, NAV per share of Tk. 15.78 and NOCFPS of Tk. 1.88 for the year ended June 30, 2024 as against Tk. 1.06, Tk. 15.02 and Tk. 2.20 respectively for the year ended June 30, 2023. (end)
The first part of this announcement is missing from the archive. - Price Limit Open
There will be no price limit on the trading of the shares of the Company today (29.10.2024) following its corporate declaration.
- Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 28, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
- Category Change
The Company will be placed in 'B' category from existing 'Z' category with effect from October 22, 2024 as the Company has reported disbursement of 2% Cash Dividend for the year ended June 30, 2023.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase the securities of Advent Pharma Limited in between 1st to 7th trading days following the change of categorization, with effect from October 22, 2024 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2023 to the respective shareholders.
- Category Change
The Company will be placed in 'Z' category from existing 'B' category with effect from September 26, 2024 as per provision 1(e) of BSEC Directive No. BSEC/CMRRCD/2009-193/77, dated May 20, 2024.
- Prohibition on providing loan facilities to purchase securities
The Stock Brokers and Merchant Bankers are requested to abstain from providing loan facilities to purchase security of Advent Pharma Limited with effect from September 26, 2024 as per BSEC Directive No. BSEC/CMRRCD/2009-193/32 dated December 26, 2021.
- Appointment of Company Secretary
The Company has informed that as per the decision of the Board of Directors, Mr. Md. Delwar Hossen has been appointed as the Company Secretary of the company.
- Q3 Financials
(Q3 Un-audited): EPS was Tk. 0.29 for January-March 2024 as against Tk. 0.28 for January-March 2023; EPS was Tk. 0.91 for July 2023-March 2024 as against Tk. 0.98 for July 2022-March 2023. NOCFPS was Tk. 1.74 for July 2023-March 2024 as against Tk. 1.60 for July 2022-March 2023. NAV per share was Tk. 15.79 as on March 31, 2024 and Tk. 15.02 as on June 30, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2024.
- Alpha Credit Rating Limited has assigned Surveillance rating of the Company as \"A-\" in the long term and \"ST-3\" in t
Alpha Credit Rating Limited has assigned Surveillance rating of the Company as \"A-\" in the long term and \"ST-3\" in the short term along with Stable outlook based on audited financial statements as on June 30, 2023 and relevant qualitative information till February 11, 2024.
- Q2 Financials
(Q2 Un-audited): EPS was Tk. 0.27 for October-December 2023 as against Tk. 0.29 for October-December 2022; EPS was Tk. 0.62 for July-December 2023 as against Tk. 0.69 for July-December 2022. NOCFPS was Tk. 1.09 for July-December 2023 as against Tk. 1.00 for July-December 2022. NAV per share was Tk. 15.50 as on December 31, 2023 and Tk. 15.02 as on June 30, 2023.
- Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2024 at 3:30 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2023.
Source: Dhaka Stock Exchange announcements. Some posts before 2014 have no title, and 2014–2020 coverage is incomplete.